Evaluation of the Efficacy and Safety of Bazedoxifene/ Conjugated Estrogens for Secondary Outcomes Including Vasomotor Symptoms in Postmenopausal Women by Years Since Menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) Trials

Bazedoxifene/conjugated estrogens (BZA/CE), a novel tissue-selective estrogen complex (TSEC), has been evaluated in the Selective estrogens, Menopause And Response to Therapy (SMART) trials. Secondary outcomes from these trials were evaluated to determine whether the effects of BZA/CE are influenced...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of women's health (Larchmont, N.Y. 2002) N.Y. 2002), 2014, Vol.23 (1), p.18-28
Hauptverfasser:	PINKERTON, JoAnn V, ABRAHAM, Lucy, BUSHMAKIN, Andrew G, CAPPELLERI, Joseph C, RACKETA, Jill, SHI, Harry, CHINES, Arkadi A, MIRKIN, Sebastian
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Dose-Response Relationship, Drug Double-Blind Method Estrogens - administration & dosage Estrogens - adverse effects Estrogens - pharmacology Estrogens, Conjugated (USP) - administration & dosage Estrogens, Conjugated (USP) - adverse effects Estrogens, Conjugated (USP) - pharmacology Female Health Status Hot Flashes - drug therapy Hot Flashes - epidemiology Humans Indoles - administration & dosage Indoles - adverse effects Indoles - pharmacology Medical sciences Middle Aged Postmenopause - drug effects Prevention and actions Public health. Hygiene Public health. Hygiene-occupational medicine Quality of Life Selective Estrogen Receptor Modulators - administration & dosage Selective Estrogen Receptor Modulators - adverse effects Selective Estrogen Receptor Modulators - pharmacology Severity of Illness Index Specific populations (family, woman, child, elderly...) Surveys and Questionnaires Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Bazedoxifene/conjugated estrogens (BZA/CE), a novel tissue-selective estrogen complex (TSEC), has been evaluated in the Selective estrogens, Menopause And Response to Therapy (SMART) trials. Secondary outcomes from these trials were evaluated to determine whether the effects of BZA/CE are influenced by years since menopause (YSM). SMART-1 and SMART-2 were randomized, double-blind, placebo (PBO)-controlled phase 3 trials in nonhysterectomized postmenopausal women. Outcomes were evaluated for women
ISSN:	1540-9996 1931-843X
DOI:	10.1089/jwh.2013.4392